Chandan Healthcare Delivers Strong Q1 FY27; Total Income at ₹82 Cr, EBITDA Surges 42% YoY to ₹21 Cr, PAT Rises 30% YoY

PNN
Lucknow, (Uttar Pradesh) [India], August 18: Chandan Healthcare Limited (NSE - CHANDAN), - Chandan Healthcare Limited, one of the leading players in Diagnostic sector having Pan India presence, has announced its unaudited Financial Results for Q1 FY27.
Consolidated Key Financial Highlights:
Q1 FY27 Consolidated Key Financial Highlights (YoY)
- Total Income of ₹ 82.26 Cr, YoY growth of 19.62%
- EBITDA of ₹ 20.98 Cr, YoY growth of 42.27%
- EBITDA Margin of 25.51%, YoY growth of 406 Bps
- PAT of ₹ 7.50 Cr, YoY growth of 29.51%
- PAT Margin of 9.11%, YoY growth of 70 Bps
- EPS of ₹ 2.59, YoY growth of 12.61%
Q1 FY27 Consolidated Key Financial Highlights (QoQ)
- Total Income of ₹ 82.26 Cr, QoQ growth of 6.24%
- EBITDA of ₹ 20.98 Cr, QoQ growth of 57.50%
- EBITDA Margin of 25.51%, QoQ growth of 830 Bps
- PAT of ₹ 7.50 Cr, QoQ growth of 52.82%
- PAT Margin of 9.11%, QoQ growth of 278 Bps
- EPS of ₹ 2.59, QoQ growth of 32.82%
For more details, visit the company's website: https://chandandiagnostic.com/
Commenting on the financial performance, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, said, "We delivered a healthy performance during the quarter, with Total Income of ₹82.26 Cr, reflecting growth of 19.62% YoY. The performance was supported by continued expansion of our diagnostic network, growing contribution from the B2G business and steady progress across our partnership-led growth initiatives.
Our network expansion gained significant momentum during the quarter, with 134 franchise centres added, taking the franchise network to 264 centres. We also added 1 Comprehensive Diagnostic Centre, 2 Diagnostic Centres and 3 standalone Labs, taking our total network to 327 centres, including franchise centres. The franchise rollout continues to progress well, enabling us to expand our reach efficiently across existing and new markets.
We also strengthened our presence in key geographies during the quarter. The acquisition of Nishkam Imaging, an established radiology and pathology centre in New Delhi, further strengthened our Delhi network, while the launch of our Vadodara centre marked our entry into Gujarat. Our rollout with Jeena Sikho hospitals and clinics is progressing well, and we plan to expand diagnostic services across additional partner facilities.
Going forward, our focus remains on accelerating the franchise rollout, further expanding our franchise footprint, scaling our partnership-led network, growing the B2G business and selectively expanding our presence across attractive markets. We remain focused on building a wider, accessible and integrated diagnostics network through a balanced expansion of franchise and owned centres, while driving sustainable growth."

About Chandan Healthcare Limited
Chandan Healthcare Limited, established in 2003, is one of India's leading providers of diagnostic and pharmacy services and a key entity of the Chandan Group. The Company delivers a comprehensive range of pathology and radiology services through its expanding network across India.
As on June 30, 2026, the Company operates 327 diagnostic centres including 264 operational franchise centres, strengthening its presence across urban, semi-urban and emerging markets. Its diagnostic portfolio comprises more than 3,000 pathology tests and 500+ radiology tests, including blood tests, X-ray, ECG, Ultrasound, CT scan, MRI and several other specialized diagnostic investigations. The Company's network includes NABL and NABH accredited pathology laboratories and radiology centres, reflecting its commitment to delivering reliable, high-quality diagnostic services.
Chandan Healthcare operates through a diversified business model comprising B2C (Retail Customers), B2B (Institutional & Corporate Clients) and B2G (Government PPP Contracts), providing a balanced and scalable revenue profile while catering to a wide spectrum of healthcare needs.
The Company was listed on the NSE Emerge platform on February 17, 2025.
During FY26, The Company reported Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and Profit After Tax (PAT) of ₹27.06 Cr, reflecting its continued operational growth and financial strength.
Disclaimer
Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)